SPRUCE BIOSCIENCES, INC. financial data

Symbol
SPRB on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 10 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 228% % -52%
Debt-to-equity 82% % 166%
Return On Equity -305% % -392%
Return On Assets -168% % -254%
Operating Margin -7100% % -1066%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1,070,370 shares -97%
Common Stock, Shares, Outstanding 563,491 shares -99%
Entity Public Float $18,800,000 USD -75%
Common Stock, Value, Issued $0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 563,066 shares 2.3%
Weighted Average Number of Shares Outstanding, Diluted 563,066 shares 2.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $697,000 USD -90%
Research and Development Expense $36,875,000 USD 2.3%
General and Administrative Expense $13,309,000 USD -6.8%
Operating Income (Loss) $49,487,000 USD -14%
Net Income (Loss) Attributable to Parent $47,879,000 USD -21%
Earnings Per Share, Basic 13 USD/shares 7.4%
Earnings Per Share, Diluted 13 USD/shares 7.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $10,669,000 USD -82%
Cash, Cash Equivalents, and Short-term Investments $10,700,000 USD -82%
Other Assets, Current $2,915,000 USD 239%
Assets, Current $14,516,000 USD -77%
Other Assets, Noncurrent $62,000 USD -88%
Assets $15,313,000 USD -76%
Accounts Payable, Current $1,386,000 USD -23%
Accrued Liabilities, Current $7,502,000 USD -3.1%
Liabilities, Current $9,427,000 USD -21%
Operating Lease, Liability, Noncurrent $500,000 USD
Other Liabilities, Noncurrent $0 USD -100%
Liabilities $9,927,000 USD -26%
Retained Earnings (Accumulated Deficit) $274,588,000 USD -21%
Stockholders' Equity Attributable to Parent $5,386,000 USD -90%
Liabilities and Equity $15,313,000 USD -76%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $12,727,000 USD 15%
Net Cash Provided by (Used in) Financing Activities $411,000 USD -81%
Net Cash Provided by (Used in) Investing Activities $0 USD -100%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 563,491 shares -99%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10,704,000 USD -82%
Deferred Tax Assets, Valuation Allowance $85,349,000 USD 27%
Deferred Tax Assets, Gross $85,546,000 USD 27%
Operating Lease, Liability $1,019,000 USD -20%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $53,036,000 USD -12%
Lessee, Operating Lease, Liability, to be Paid $1,159,000 USD -23%
Operating Lease, Liability, Current $283,000 USD 13%
Lessee, Operating Lease, Liability, to be Paid, Year Two $365,000 USD 3.1%
Lessee, Operating Lease, Liability, to be Paid, Year One $354,000 USD 3.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $140,000 USD -40%
Lessee, Operating Lease, Liability, to be Paid, Year Three $376,000 USD 3%
Deferred Tax Assets, Operating Loss Carryforwards $35,484,000 USD 6.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $4,348,000 USD 34%
Lessee, Operating Lease, Liability, to be Paid, Year Four $64,000 USD -83%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $197,000 USD -21%
Share-based Payment Arrangement, Expense $1,843,000 USD -67%
Interest Expense $140,000 USD -61%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%